Evidence map›Paper›PMID 31767869›Full record

ArticleNature communications2019

LncRNA REG1CP promotes tumorigenesis through an enhancer complex to recruit FANCJ helicase for REG3A transcription.

Hamed Yari, Lei Jin, Liu Teng, Yufang Wang, Yongyan Wu, Guang Zhi Liu, Wei Gao, Jin Liang, Yanfeng Xi, Yu Chen Feng and 13 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. The relevance of RNA-DNA interactions as regulators of physiological functions.Pflugers Archiv : European journal of physiology · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. A New Strategy to Investigate RNA:DNA Triplex Using Atomic Force Microscopy.International journal of molecular sciences · 2024
    Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 2 countries.

Hamed YariSchool of Biomedical Sciences and Pharmacy, School of Medicine and Public Health, School of Environmental and Life Sciences, The University of Newcastle, Newcastle, NSW, 2308, Australia.ORCID http://orcid.org/0000-0002-4008-3504
Lei JinSchool of Biomedical Sciences and Pharmacy, School of Medicine and Public Health, School of Environmental and Life Sciences, The University of Newcastle, Newcastle, NSW, 2308, Australia.
Liu TengTranslational Research Institute, Henan Provincial People's Hospital, The Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450053, China.
Yufang WangDepartment of Pathophysiology, School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan, 610041, China.
Yongyan WuDepartment of Otolaryngology, Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, the first affiliated hospital, Shanxi Medical University, Taiyuan, Shanxi, 030001, China.
Guang Zhi LiuTranslational Research Institute, Henan Provincial People's Hospital, The Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450053, China.
Wei GaoDepartment of Otolaryngology, Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, the first affiliated hospital, Shanxi Medical University, Taiyuan, Shanxi, 030001, China.ORCID http://orcid.org/0000-0001-7836-2851
Jin LiangDepartment of Molecular Biology, Department of Pathology, Shanxi Cancer Hospital and Institute, Shanxi Medical University, Taiyuan, Shanxi, 030013, China.
Yanfeng XiDepartment of Molecular Biology, Department of Pathology, Shanxi Cancer Hospital and Institute, Shanxi Medical University, Taiyuan, Shanxi, 030013, China.
Yu Chen FengSchool of Biomedical Sciences and Pharmacy, School of Medicine and Public Health, School of Environmental and Life Sciences, The University of Newcastle, Newcastle, NSW, 2308, Australia.ORCID http://orcid.org/0000-0001-5507-8129
Chunming ZhangDepartment of Otolaryngology, Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, the first affiliated hospital, Shanxi Medical University, Taiyuan, Shanxi, 030001, China.
Yuan Yuan ZhangSchool of Biomedical Sciences and Pharmacy, School of Medicine and Public Health, School of Environmental and Life Sciences, The University of Newcastle, Newcastle, NSW, 2308, Australia.ORCID http://orcid.org/0000-0001-5851-5128
Hessam TabatabaeeSchool of Biomedical Sciences and Pharmacy, School of Medicine and Public Health, School of Environmental and Life Sciences, The University of Newcastle, Newcastle, NSW, 2308, Australia.ORCID http://orcid.org/0000-0001-8912-1746
Ting LaSchool of Biomedical Sciences and Pharmacy, School of Medicine and Public Health, School of Environmental and Life Sciences, The University of Newcastle, Newcastle, NSW, 2308, Australia.ORCID http://orcid.org/0000-0001-6072-5722
Rui Hong YangDepartment of Molecular Biology, Department of Pathology, Shanxi Cancer Hospital and Institute, Shanxi Medical University, Taiyuan, Shanxi, 030013, China.
Fu Hua WangDepartment of Molecular Biology, Department of Pathology, Shanxi Cancer Hospital and Institute, Shanxi Medical University, Taiyuan, Shanxi, 030013, China.
Xu Guang YanSchool of Biomedical Sciences and Pharmacy, School of Medicine and Public Health, School of Environmental and Life Sciences, The University of Newcastle, Newcastle, NSW, 2308, Australia.ORCID http://orcid.org/0000-0001-5995-8537
Margaret FarrellySchool of Biomedical Sciences and Pharmacy, School of Medicine and Public Health, School of Environmental and Life Sciences, The University of Newcastle, Newcastle, NSW, 2308, Australia.
Rodney ScottSchool of Biomedical Sciences and Pharmacy, School of Medicine and Public Health, School of Environmental and Life Sciences, The University of Newcastle, Newcastle, NSW, 2308, Australia.ORCID http://orcid.org/0000-0001-7724-3404
Tao LiuChildren's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, NSW, 2750, Australia.ORCID http://orcid.org/0000-0001-6244-7316
Rick F ThorneSchool of Biomedical Sciences and Pharmacy, School of Medicine and Public Health, School of Environmental and Life Sciences, The University of Newcastle, Newcastle, NSW, 2308, Australia.ORCID http://orcid.org/0000-0001-7882-7081
Su Tang GuoDepartment of Molecular Biology, Department of Pathology, Shanxi Cancer Hospital and Institute, Shanxi Medical University, Taiyuan, Shanxi, 030013, China. sutangguo@aliyun.com.
Xu Dong ZhangSchool of Biomedical Sciences and Pharmacy, School of Medicine and Public Health, School of Environmental and Life Sciences, The University of Newcastle, Newcastle, NSW, 2308, Australia. Xu.Zhang@newcastle.edu.au.ORCID http://orcid.org/0000-0001-9457-8003
University of Newcastle Australia · AUShanxi Medical University · CNZhengzhou University · CNSichuan University · CNUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein products of the regenerating islet-derived (REG) gene family are important regulators of many cellular processes. Here we functionally characterise a non-protein coding product of the family, the long noncoding RNA (lncRNA) REG1CP that is transcribed from a DNA fragment at the family locus previously thought to be a pseudogene. REG1CP forms an RNA-DNA triplex with a homopurine stretch at the distal promoter of the REG3A gene, through which the DNA helicase FANCJ is tethered to the core promoter of REG3A where it unwinds double stranded DNA and facilitates a permissive state for glucocorticoid receptor α (GRα)-mediated REG3A transcription. As such, REG1CP promotes cancer cell proliferation and tumorigenicity and its upregulation is associated with poor outcome of patients. REG1CP is also transcriptionally inducible by GRα, indicative of feedforward regulation. These results reveal the function and regulation of REG1CP and suggest that REG1CP may constitute a target for cancer treatment.

Indexed as

Transcription, GeneticBiomarkers, TumorCarcinogenesisCell LineCell Line, TumorDNAEnhancer Elements, GeneticFanconi Anemia Complementation Group ProteinsHT29 CellsHumansNeoplasmsPancreatitis-Associated ProteinsPromoter Regions, GeneticRNA HelicasesRNA, Long NoncodingBiomarkers, TumorBRIP1 protein, humanDNAFanconi Anemia Complementation Group ProteinsPancreatitis-Associated ProteinsREG3A protein, humanRNA HelicasesRNA, Long Noncodingtriplex DNA

Identifiers

PMID31767869
PMCPMC6877513
OpenAlexW2989676778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.